2017-02-16

Olink Proteomics announces the availability of three additional biomarker panels focused on key biological processes with broad clinical relevance

Uppsala, Sweden, February 16, 2017 – Olink Proteomics today announced the launch of three new precision proteomics panels, further expanding its rapidly growing library of high quality human protein biomarker assays to almost 1000. The focus areas for these three new panels are Cardiometabolic, Cell Regulation and Development.

For scientists in academic/clinical research and the pharmaceutical industry, this will enable proteomic studies that cast a wider net, to discover new combinations of biomarkers that may identify clinically relevant protein signatures. Such studies are of great value for a range of applications, such as gaining a better understanding of biology and pathophysiology, patient stratification, predicting disease and treatment outcomes, wellness studies linking lifestyle with health and disease, identification of new drug targets, and identifying surrogate markers for safety and efficacy.

The biomarker assays for these new panels were selected and categorized after extensive consultation with widely used on-line bioinformatic databases. The protein composition of the panels is categorized by biological function, disease area, tissue expression and protein class, and this information is freely available on the Olink website:

As with Olink’s previous offerings, each panel offers simultaneous analysis of 92 protein biomarkers using just 1 µL of biological sample. All assays are subject to strict technical validation and QC control procedures, and each panel is optimized for the dynamic range of measurable protein concentrations.

“Olink is firmly committed to provide the tools required to enable proteomics-based breakthroughs in knowledge and understanding that will be necessary for healthcare to move towards precision medicine as quickly and efficiently as possible. The product development program we have successfully concluded in the last year demonstrates this commitment, increasing our panel portfolio from 5 to 12, and the total number of validated protein assays from around 400 to almost 1000. This offers our customers a true proteomics-scale solution for targeted biomarker discovery (covering up to one third of the plasma proteome), combined with the flexibility of disease or biological process-focused panels, to meet their varied needs. In addition, we are continuing to develop our biostatistical and bioinformatic support capabilities to better serve our customers through the whole process from study design, through data interpretation and understanding the biological implications of the results. We have been greatly encouraged during the past year by the rapid increase in the number of studies using Olink’s panels, and to see how quickly the number of scientific publications is growing. This just inspires us even further to meet the current and future needs and expectations of our customers”

says Andrea Ballagi, VP Sales & Marketing at Olink Proteomics.

Product and technology information
Each panel offers high-throughput multiplex immunoassays that measure 92 proteins simultaneously using only one microliter of serum, plasma, tumor cell lysate, or almost any other type of biological sample. Thousands of samples per week can be analyzed using these panels, which greatly accelerates the speed of protein biomarker discovery.

Olink’s assays are based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables the panels to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques. An animation overviewing how the technology works and what it is used for can be viewed on Olink’s YouTube channel.

For research use only. Not for use in diagnostic procedures.

About Olink Proteomics
Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics’ groundbreaking solutions help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Our immunoassay panels enable rapid, high-throughput analysis with exceptional data quality and minimal consumption of precious biological samples. Only 1 µL of sample is needed to address 92 biomarkers simultaneously and each panel is sufficient for 96 samples, generating more than 9 000 data points from each run. Each panel is focused on a specific area of disease or biology, targeting 92 validated and/or exploratory biomarkers that have been carefully selected in collaboration with leading experts in the field. All assays are rigorously quality controlled and our validation data is made freely available. Customers can obtain the panels as ready-to-use kits to run the assays themselves, or can choose to let our in-house experts run their samples for them, using our Analysis Service in Uppsala or Boston.

Olink Proteomics is headquartered in Uppsala, Sweden, with a regional office and service laboratory for the U.S. organization in Watertown, MA.

For more information, please visit www.olink.com.

Proseek® is a registered trademark of Olink Proteomics AB.

Olink® is a registered trademark of Olink Bioscience AB.

Contact information
Andrea Ballagi, MD, PhD, MBA
VP Sales & Marketing
Phone: +46-18-444 3970
E-mail: [email protected]/* */!function(t,e,r,n,c,a,p){try{t=document.currentScript||function(){for(t=document.getElementsByTagName('script'),e=t.length;e--;)if(t[e].getAttribute('data-cfhash'))return t[e]}();if(t&&(c=t.previousSibling)){p=t.parentNode;if(a=c.getAttribute('data-cfemail')){for(e='',r='0x'+a.substr(0,2)|0,n=2;a.length-n;n+=2)e+='%'+('0'+('0x'+a.substr(n,2)^r).toString(16)).slice(-2);p.replaceChild(document.createTextNode(decodeURIComponent(e)),c)}p.removeChild(t)}}catch(u){}}()/* */


This news release was sent using Mynewsdesk - http://www.mynewsdesk.com

CONTACT WEBMASTER | SHARE
EU Vinnova